ABBV

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Abbvie Inc

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
CEO
Richard Gonzalez
Employees
2022
Headquarters

1 N Waukegan Rd
North Chicago, Illinois 60064-1802
Phone: 18479327900
www.abbvie.com

News

Tech sector thrives amid mixed market signals: Insights from today''s trading landscape
Jul 15, 2024 13:46pm

Today''s stock market presented a patchwork of performances, with significant movement observed in the technology sector, particularly semiconductors and consumer electronics. Tech and Consumer Electronics Lead the Charge The heatmap of today’s trading activity highlights a robust performance in the tech sector. Apple (AAPL) significantly outpaced its peers with a gain of 2.26%, indicating strong investor confidence, possibly bolstered by positive news or product announcements. On the other hand, the semiconductor segment showed a modest uptick, with Nvidia (NVDA) up by 1.28% and Advanced Micro Devices (AMD) rising by 2.04%, reflecting a recovering sentiment after recent turbulent weeks. Mixed Results in Other Sectors Contrasting the brightly colored tech sector, consumer cyclicals and healthcare showed some strain. Amazon (AMZN) slightly dipped by 0.37%, despite an overall stability in the internet retail sub-sector. Similarly, the healthcare sector depicted a mixed bag, with UnitedHealth (UNH) making a notable leap of 2.41%, while AbbVie (ABBV) saw a decline of 0.71%, illustrating the heterogeneous reactions to market forces and regulatory news within this field.


Source:Forexlive
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In ''Long-Standing'' AndroGel Case
Jul 12, 2024 17:39pm

AbbVie Inc (NYSE: ABBV ) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications . The pharmaceutical company is seeking to overturn a decision by the 3rd U.S. Circuit Court of Appeals, stating that filing a sham patent-infringement lawsuit could override attorney-client privilege. The case stems from allegations in the Philadelphia federal court where drug wholesalers, including Cencora Inc (NYSE: COR ) (formerly AmerisourceBergen) and McKesson Corporation (NYSE: MCK ), claim they were overcharged for the testosterone replacement drug AndroGel. Also Read: AbbVie’s Parkinson’s Disease Therapy Hits FDA Roadblock . The wholesalers allege that AbbVie filed a … Full story available on Benzinga.com


Source:Benzinga
AbbVie seeks FDA, EMA nod for GCA drug upadacitinib
Jul 12, 2024 15:00pm

https://www.investing.com/news/company-news/abbvie-seeks-fda-ema-nod-for-gca-drug-upadacitinib-93CH-3517643


Source:Investing.com
AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis
Jul 12, 2024 13:06pm

WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EM…


Source:Finanz Nachrichten
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis | ABBV Stock News
Jul 12, 2024 12:30pm

AbbVie seeks FDA and EMA approval for upadacitinib to treat giant cell arteritis, showing promising Phase 3 results with sustained remission and a consistent safety profile.


Source:Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Jul 11, 2024 20:01pm


Source:Kwhen Finance
AbbVie asks US Supreme Court to weigh protections for attorney records
Jul 11, 2024 16:40pm

Pharmaceutical company AbbVie has asked the U.S. Supreme Court to take up its fight to protect corporate records, warning that a lower court ruling threatens to erode the shield that keeps most attorney communications off-limits from a company''s courtroom opponents.


Source:Reuters
Burn Pain Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
Jul 10, 2024 15:45pm

Burn Pain companies are Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, and others. LAS VEGAS, NEVADA, UNITED STATES, July 10, 2024 /⁨EINPresswire.com⁩/ -- DelveInsight’s “Burn …


Source:EIN News Pharmaceuticals
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
Jul 10, 2024 12:00pm

NORTH CHICAGO, Ill., July 10, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of executive vice president, research & development…


Source:PR Newswire
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer | ABBV Stock News
Jul 10, 2024 12:00pm

AbbVie names Roopal Thakkar as EVP of R&D, bringing fresh perspectives to its global pipeline. CEO praises her strategic prowess amid Thomas Hudson''s retirement.


Source:Stock Titan